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Abstract
Medication‑related osteonecrosis of the jaw (MRONJ) is a severe adverse drug reaction, consisting of 
progressive bone destruction in the maxillofacial region of patients. ONJ can be caused by two pharmacological 
agents: Antiresorptive (including bisphosphonates (BPs) and receptor activator of nuclear factor kappa‑B 
ligand inhibitors) and antiangiogenic. MRONJ pathophysiology is not completely elucidated. There are 
several suggested hypothesis that could explain its unique localization to the jaws: Inflammation or infection, 
microtrauma, altered bone remodeling or over suppression of bone resorption, angiogenesis inhibition, soft 
tissue BPs toxicity, peculiar biofilm of the oral cavity, terminal vascularization of the mandible, suppression 
of immunity, or Vitamin D deficiency. Dental screening and adequate treatment are fundamental to reduce 
the risk of osteonecrosis in patients under antiresorptive or antiangiogenic therapy, or before initiating the 
administration. The treatment of MRONJ is generally difficult and the optimal therapy strategy is still to be 
established. For this reason, prevention is even more important. It is suggested that a multidisciplinary team 
approach including a dentist, an oncologist, and a maxillofacial surgeon to evaluate and decide the best therapy 
for the patient. The choice between a conservative treatment and surgery is not easy, and it should be made on 
a case by case basis. However, the initial approach should be as conservative as possible. The most important 
goals of treatment for patients with established MRONJ are primarily the control of infection, bone necrosis 
progression, and pain. The aim of this paper is to represent the current knowledge about MRONJ, its preventive 
measures and management strategies.
Key words: Bisphosphonate‑associated osteonecrosis of the jaw, bone metastases, drug therapy, medication‑related 
osteonecrosis of the jaw, osteoporosis
INTRODUCTION
Medication‑related osteonecrosis of the jaw (MRONJ) is 
a severe adverse drug reaction, consisting of progressive 
bone destruction in the maxillofacial region of patients.
In 2014, the American Association of Oral and 
Maxillofacial Surgeons (AAOMSs) suggested to 
change the nomenclature from bisphosphonate‑ 
related osteonecrosis of the jaw (BRONJ) 
to MRONJ to accommodate the growing 
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number of osteonecrosis cases involving the 
maxilla and mandible associated with other 
antiresorptive (denosumab) and antiangiogenic 
therapies.[1,2] The aim of this paper is to represent 
the current knowledge about MRONJ, its preventive 
measures and management strategies.
MEDICATION‑RELATED OSTEONECROSIS OF 
THE JAW RELATED MEDICATION
Osteonecrosis of the jaw (ONJ) can be caused by two 
pharmacological agents: Antiresorptive (including 
bisphosphonates (BPs) and receptor activator of nuclear 
factor kappa‑B ligand [RANK‑L] inhibitors) and 
antiangiogenic.
BPs can be divided into aminobisphosphonates (NBPs) 
and non‑NBPs on the basis of an amino functional 
group presence in the molecule. NBPs are the one 
involved in the ONJ [Table 1].
Intravenous (IV) BPs are utilized to treat conditions 
associated with cancer as well as hypercalcemia of 
malignancy, skeletal‑related events connected with bone 
metastases from solid tumor and for the management of 
lytic lesion related to multiple myeloma.[3‑6]
Oral BPs are used to treat osteoporosis,[7] osteopenia,[8] 
or other less common conditions such as Paget’s disease 
and osteogenesis imperfecta.[9]
RANK ligand inhibitor (denosumab) is an 
antiresorptive medication that inhibits osteoclast 
function, decreases bone resorption, and increases 
bone density.[10,11] It is used in patients affected by 
osteoporosis or metastatic bone diseases.
Antiangiogenic medications hinder the development of 
novel blood vessels, blocking the angiogenesis‑signaling 
cascade. They are basically divided into two types of 
drugs: Monoclonal antibodies that stop the receptor 
or growth factor (bevacizumab) and small molecules, 
which determine the block by binding the tyrosine 
kinase receptor (sunitinib and sorafenib). It has been 
hypothesized that they facilitate the other anticancer 
agents delivery.[12]
MRONJ pathophysiology is not completely 
elucidated.[13,14] There are several suggested hypothesis 
that could explain its unique localization to the jaws: 
Inflammation or infection, microtrauma, altered bone 
remodeling or over suppression of bone resorption, 
angiogenesis inhibition, soft tissue BPs toxicity, peculiar 
biofilm of the oral cavity, terminal vascularization of 
the mandible, suppression of immunity, or Vitamin D 
deficiency.[13,15‑18]
Three risk factors such as local factors, underlying 
disease, and kind of medication [Table 2] should 
be considered. To explain the MRONJ disease 
frequency value, we have to consider two criteria: 
Therapeutic indications (osteoporosis/osteopenia and 
malignancy) and type of medication (BP and non‑BP). 
The ONJ risk in patients treated with zolendronate 
is 50–100 times superior to individuals treated by 
placebo. The MRONJ risk in cancer patients treated 
by denosumab is similar to the possibility of ONJ in 
patients exposed to zolendronate.[13,19] As reported in 
Table 3, the risk of MRONJ is different on the basis 
of the medications and the administrations.[21‑27] Even 
if the ONJ risk is similar, it is important to underline 
a substantial difference between BRONJ and 
DRONJ (denosumab‑related ONJ). BRONJ occurs 
after a mean administration of 33 months (IV 
Table 1: Medication‑related osteonecrosis of the 
jaw‑related medications
Molecule Category Indication Trade 
name
Alendronate Bisphosphonate Osteoporosis Fosamax
Bevacizumab Humanized 
monoclonal 
antibody
Metastatic colorectal 
carcinoma, 
nonsquamous nonsmall 
cell lung carcinoma, 
glioblastoma, 
metastatic renal cell 
carcinoma
Avastin
Denosumab Receptor activator 
of  nuclear factor 
kappa-B-ligand 
inhibitors
Bone metastases 
osteoporosis
Xgeva
Prolia
Ibandronate Bisphosphonate Osteoporosis Boniva
Neridronate Bisphosphonate Osteogenesis imperfect 
Paget’s disease of  bone
Nerixia
Pamidronate Bisphosphonate Bone metastases Aredia
Risedronate Bisphosphonate Osteoporosis Actonel
Sirolimus Mammalian target 
of  rapamycin 
pathway
Organ rejection in 
renal transplant
Rapamune
Sorafenib Tyrosine kinase 
inhibitors
Hepatocellular 
carcinoma, renal cell 
carcinoma
Nexavar
Sunitib Tyrosine kinase 
inhibitors
Gastrointestinal 
stromal tumor, 
renal cell carcinoma, 
pancreatic 
neuroendocrine tumor
Sutent
Tiludronate Bisphosphonate Paget’s disease of  bone Skelid
Zolendronate Bisphosphonate Bone metastases 
osteoporosis
Zometa 
Reclast
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administration in cancer patients) or 48 months (oral 
administration in osteoporotic patients). DRONJ occurs 
early after treatment, independently of the number of 
previous administrations. Hence, ONJ risk after the 
use of RANK‑L inhibitors decreases monthly while BP 
drugs remain stable for years. Risk of BRONJ is directly 
related to the duration of the therapy and total amount 
of the medication. Risk factors for MRONJ are reported 
in Table 2. Oral surgery is one of the greatest risk factors 
for MRONJ: According to several authors, 52–61% 
of patients reported tooth extraction as a precipitating 
event.[20,28] The risk of ONJ in patients treated by 
oral‑BPs after a tooth extraction is 0.5%; ONJ risk in 
patients with cancer treated with IV BPs ranges from 
1.6% to 14.8%.[29] MRONJ appears more frequently 
in the mandible (73%) compared to maxilla (22.5%); it 
involves both jaws in 4.5% of the cases.[28]
DEFINITION AND STAGING SYSTEMS
Patients are affected by MRONJ if all the following 
clinical manifestations are demonstrated:
•	 	Ongoing	 or	 antecedent	 treatment	 with	
antiangiogenic or antiresorptive drugs
•	 	No	patient	history	of	 radiation	 therapy	or	manifest	
metastasis to the jaw
•	 	Exposed	 bone	 or	 presence	 of	 an	 intraoral	 or	
extraoral fistula in the maxillofacial region persisting 
for more than 8 weeks.[1]
However, many authors disagree with the last 
definition. Hence, the exposed necrotic bone in the 
oral cavity is just one of the possible manifestations of 
BRONJ, and it is not found in all patients. In 2012, 
the SICMF (Italian Society for Maxillofacial Surgery) 
and the SIPMO (Italian Society of Oral Pathology and 
Medicine) proposed a new definition:[30] “BRONJ is 
an adverse drug reaction described as the progressive 
destruction and death of bone that affects the mandible 
or maxilla of patients exposed to the treatment with 
nitrogen‑containing BPs, in the absence of a previous 
radiation treatment.” It was supported by a study[31] on a 
large population of European patients. According to the 
AAOMS definition, just the 76% of the BRONJ were 
diagnosed; 24% remaining ONJ could not be diagnosed 
because of nonvisible necrotic bone.
BRONJ staging systems are copious, and most of 
them are based on clinical findings: In 2006, Ruggiero 
et al.[16] proposed a clinical staging system with three 
different clinical levels based on signs and symptoms; 
in 2009, the AAOMSs implemented it with Stage 0.[2] 
Marx,[32] in 2007, was the only one who divided the 
stages on the basis of the lesion’s size. Bedogni et al.,[30] 
in 2012, proposed a clinical‑radiological staging system. 
Different BRONJ staging systems are given in Table 4.
PREVENTION OF MEDICATION‑RELATED 
OSTEONECROSIS OF THE JAW
Dental screening and adequate treatment are 
fundamental to reduce the risk of ONJ in patients 
under antiresorptive or antiangiogenic therapy or before 
initiating the administration.[28,33‑35] The treatment of 
MRONJ is generally difficult, and the optimal therapy 
strategy is still to be established. For this reason, 
prevention is even more important. Several authors 
suggested a “drug holiday” before teeth extractions 
or other invasive procedures. However, there is no 
Table 2: Medication‑related osteonecrosis of the 
jaw risk factors
Medication-related 
risk factors
Molecule Way of  administration
Total amount Length of  the therapy
Systemic and other 
risk factors
Disease Concurrent pathologies (diabetes, 
rheumatoid arthritis, dialysis, anemia, 
hypocalcemia, immunosuppression, 
osteomalacia)
Genetic factors Age
Eripoietic factors Obesity
Tobacco Sex
Steroid therapy Alcohol
Local factors-related 
risk factors
Microtrauma Inflammatory disease
Oral surgery Removable prosthesis
Anatomic conditions Oral implantology
Table 3: Osteonecrosis of the jaw risk (cases per 10,000 patients)
Therapy Osteoporotic patients Therapy Cancer patients
Placebo[21,22] 0-2×10,000 Placebo[24-26] 0-1,9×10,000
Oral bisphosphonates <4 years[23] 10×10,000 Zolendronate[19,20,24-26] 33-110×10,000
Oral bisphosphonates >4 years[23] 21×10,000 Bevacizumab[27] 20×10,000
Zolendronate for 3 years[21] 1,7×10,000 Zolendronate + Bevacizumab[27] 90×10,000
Denosumab[22] 4×10,000 Denosumab[19,25] 70-190×10,000
Rosella, et al.: MRONJ: Diagnosis, treatment, and prevention
Journal of International Society of Preventive and Community Dentistry    100March-April 2016, Vol. 6, No. 2
unanimous consensus on this treatment and not 
enough data to support the cessation of medical 
treatment in patients with osteoporosis. Currently, 
AAOMS considers appropriate drug holiday procedure 
as reported by Damm and Jones in “at risk” patients 
with extended exposure history (>4 years).[36] Even 
in cancer, individuals receiving IV therapy, there are 
limited data about the consequence of interrupting 
BPs IV administration before surgical procedures. If is 
allowed by patient conditions, the oncologist should 
consider to stop the therapy until the healing of soft 
tissue has occurred.[36] As part of a preventive approach, 
a distinction needs to be made between IV and oral 
therapy in patients under medical treatment or about to 
initiate it.
Cancer patients about to initiate intravenous 
medical treatment
Prior to the beginning of an IV medical treatment, 
the patient should always be carefully evaluated by a 
dentist. The main goals of preventive dental measures 
are to remove any oral infection, pathology, or risk 
factors in order to obtain a stable oral health situation, 
preventing the necessity for invasive dental procedures 
in the near or intermediate future.[37] Extraction of 
partially embedded teeth should be performed at this 
time. Embedded teeth completely covered by bone 
and soft tissue without any communication with the 
oral cavity should be left undisturbed.[38] Conservative 
endodontic and prosthodontic therapies of teeth with 
Table 4: Different bisphosphonate related osteonecrosis of the jaw staging systems
Stage Marx 2007[32] AAOMS 2009[2] SICMF–SIPMO 2012[30]
At risk 
category
No evidence of  exposed or 
necrotic bone in patients 
who have been treated with 
bisphosphonates
Stage 0 Subclinical damage, microscopically 
represented by beginner 
hypocellularity osteoclast apoptosis 
and decrease of  endosteal osteoblast
Nonspecific clinical findings 
and symptoms such as jaw pain 
or osteosclerosis but no clinical 
evidence of  exposed bone
Stage 1 A: Painless exposed bone <1 cm
B: Painless exposed bone >1 cm
Exposed/necrotic bone in 
patients who are asymptomatic 
and who have no evidence of  
infection
Focal BRONJ
Clinical signs and symptoms: Bone exposure; sudden 
dental mobility; nonhealing postextraction socket; 
mucosal fistula; swelling; abscess formation; trismus; 
gross mandibular deformity; and/or hypoesthesia/
paraesthesia of  the lips
CT finding: Increased bone density limited to the 
alveolar bone region (trabecular thickening and/or 
focal osteosclerosis), with or without the following 
signs: Markedly thickened and sclerotic lamina dura; 
persisting alveolar socket; and/or cortical disruption
1a: Asymptomatic
1b: Symptomatic (pain and purulent discharge)
Stage 2 A: Painful and infected single 
exposed bone<2 cm
B: Painful and infected single 
exposed bone>2 cm
Exposed/necrotic bone 
associated with infection 
as evidenced by pain and 
erythema in the region of  the 
exposed bone with or without 
purulent drainage
Diffuse BRONJ
Clinical signs and symptoms: The same as Stage 1
CT findings: Increased bone density extended to the 
basal bone (diffuse osteosclerosis), with or without the 
following signs: Prominence of  the inferior alveolar 
nerve canal; periosteal reaction; sinusitis; sequestra 
formation; and/or oroantral fistula
1a: Asymptomatic
1b: Symptomatic (pain and purulent discharge)
Stage 3 A: Multiple exposed bone areas 
without clinical findings of  
osteolysis, orocutaneous fistula, or 
pathological fractures
B: Exposed bone >3 cm or with 
clinical findings of  osteolysis, or 
orocutaneous fistula, or pathological 
fractures
Exposed/necrotic bone in 
patients with pain, infection, 
and one or more of  the 
following: Pathologic fracture, 
extraoral fistula, or osteolysis 
extending to the inferior 
border or sinus floor
Complicated BRONJ
The same as Stage 2, with one or more of  the following
Clinical signs and symptoms: Extraoral
fistula; displaced mandibular stumps; nasal leakage of  
fluids
CT findings: Osteosclerosis of  adjacent bones (zygoma, 
hard palate); pathologic mandibular fracture; and/or 
osteolysis extending to the sinus floor
AAOMS=American association of  oral and maxillofacial surgeons, SICMF=Italian society for maxillofacial surgery, SIPMO=Italian society of  oral pathology and 
medicine, BRONJ=Bisphosphonate related osteonecrosis of  the jaw, CT=Computed tomography
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good prognosis should be completed. Periodontal 
stabilization splints for teeth with Grades 1–2 mobility 
in patients with good dental hygiene and extraction in 
patients with poor dental hygiene are necessary.[35,37] If 
allowed by general health conditions, the beginning of 
antiangiogenic or antiresorptive treatment should be 
deferred as far as oral status is stable or, at least, until the 
surgical site has mucosalized (2–3 weeks).[1]
Inadequate dentures should be modified, rebased, or 
replaced to decrease the oral tissue pressure and to prevent 
sore spots, especially along the lingual flange region or at 
the mandibular tori. Patients should achieve a proper oral 
hygiene and be educated to report any grief, inflammation, 
or bone exposure. Patients should be included in a 
periodic clinical‑radiological follow‑up, the frequency of 
which is based on the medical administration, the number 
of risk factors, and oral health status.
Asymptomatic cancer patients receiving intravenous 
medical treatment
It is essential that a detailed oral evaluation with 
regular check‑ups every 4–6 months for exposed 
bone and “early stage” MRONJ diagnosis. An 
orthopantomography every 6–12 months for 
radiographic evidence of osteosclerosis or osteolysis, 
widened periodontal ligament spaces, or furcation 
involvements should be performed.[37] A good oral 
hygiene is essential to prevent dental infections that 
may require dentoalveolar surgery. Indeed, every 
invasive procedure that involves bone injury should 
be avoided. Nonrestorable teeth should be treated by 
removal of the crown and endodontic treatment of the 
remaining roots.[39] Teeth with mobility Grades 1–2 
should be splinted rather than removed only in the 
absence of dental/periodontal lesions; extraction of teeth 
with mobility Grade 3 and/or endodontal‑periodontal 
lesion it should be completed with the minimum bone 
injury and providing antibiotic treatment. An antibiotic 
prophylaxis for surgery procedures is necessary: 
Penicillin remains the first choice, in case of penicillin 
allergy, a combination of quinolones‑metronidazole or 
erythromycin‑metronidazole is a valuable alternative. 
Inadequate dentures should be modified, rebased, 
or replaced and in case of fixed prosthodontics, the 
biological width should be respected. Elective surgery 
and dental implants placement should be avoided.
Osteoporotic patients about to start oral medical 
treatment
Starting the therapy, patients should be instructed to the 
risk of developing MRONJ, especially if the treatment 
exceed beyond 4 years.[23] Informative and educational 
documents about the current knowledge of MRONJ 
as well as the instruction to quickly report every signs 
and symptoms should be given to patients. Periodic 
clinical‑radiological follow‑ups are recommended. The 
importance of oral hygiene and dental health should 
be underlined.[1] Implant placement is possible but a 
cautious approach is suggested. Data are limited, so an 
informed consent for a nonquantifiable risk of long 
term developing of MRONJ should be obtained.
Osteoporotic patients receiving oral medical 
treatment
The risk of developing MRONJ associated with oral 
BPs is very low, and it increases when the duration 
of therapy exceeded 4 years.[23] This period should 
be decreased in the case of comorbidities as well as 
antiangiogenic or chronic corticosteroid drugs.[28,35] 
However, the risk of MRONJ in patients treated with 
oral BPs is lower compared to subjects treated with 
IV medications. Elective dentoalveolar surgery is not 
contraindicated in these patients.
Patients treated with oral‑aminobisphosphonate for 
<4 years without risk factors
No modification or delay of surgery is necessary, and 
all dental procedures are possible in this group. The 
importance of oral hygiene and dental health should be 
underlined.[1] Informative and educational documents 
about the current knowledge of MRONJ as well as the 
instruction to quickly report every signs and symptoms 
should be given to the patient.
Patients treated with oral‑aminobisphosphonate for 
<4 years with risk factors or for >4 years
The patient should be motivated to achieve and 
maintain an optimal level of oral health.[1] A detailed 
oral evaluation with regular check‑ups for exposed 
bone and “early stage” MRONJ diagnosis is suggested. 
An orthopantomography every 6–12 months for 
radiographic evidence of osteonecrosis should be 
performed. Teeth with mobility Grades 1–2 should be 
splinted whereas teeth with mobility Grade 3 should 
be extracted with minimum bone injury. An antibiotic 
prophylaxis for surgery procedures is necessary.[38] 
Inadequate dentures should be modified, rebased, or 
replaced and in case of fixed prosthodontics, the 
biological width should be respected. Endodontic 
procedures should be preferred to dental surgery. 
Implant placement is possible, but the patient should be 
informed about the possibility of short and long term 
loss of dental implants and ONJ risk.
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TREATMENT OF MEDICATION‑RELATED 
OSTEONECROSIS OF THE JAW
Treatment of ONJs is a demanding challenge for 
clinicians, and an effective and appropriate MRONJ 
therapy is still to be decided. It is suggested a 
multidisciplinary team approach including a dentist, 
an oncologist, and a maxillofacial surgeon to evaluate 
and decide the best therapy for patient. The choice 
between a conservative treatment and surgery is 
not easy, and it should be made on a case by case 
basis. However, the initial approach should be as 
conservative as possible. The most important goals 
of treatment for patients with established MRONJ 
are primarily the control of infection, bone necrosis 
progression and pain.[1]
At risk category
Patients are in this group if they have a treatment 
history with antiresorptive or antiangiogenic drugs. 
They do not need any treatment.[1] Anyway, they should 
be educated to the risk of developing MRONJ such as 
instructed to quickly report every signs and symptoms. 
Local risk factors management and periodical clinical 
and radiological check‑ups are suggested.
Stage 0
A medical treatment (antiseptic, analgesic, antibiotic, 
and antiphlogistic therapy) and management of local 
risk factors are indicated.[1] Low‑level laser therapy 
is a possible choice for treatment of osteonecrosis by 
helping reparative process, improving osteoblastic 
index, and stimulating lymphatic and blood capillaries 
growth.[39,40] A careful follow‑up for the evolution to a 
greater stage is necessary.
Stage 1
If exposed and necrotic bone or fistulae are present, they 
are rinsed with antiseptic fluids and covered with an 
adhesive paste, 3 times a day. In the absence of healing 
tendency, after 8 weeks, it is possible for a surgical 
debridement approach.[41]
Stage 2
After 2 weeks of medical therapy to reduce 
inflammatory symptoms, a surgical debridement is 
indicated. It should be more conservative as possible 
but extended as large as necessary to a complete removal 
of affected bone.[41] Antibiotic and antiphlogistic 
treatments are administered. Follow‑up examinations 
are necessary.
Stage 3
Marginal or segmental osteotomies are recommended 
for severe cases.[42‑46] Invasive surgery is indicated only 
if it could improve patient’s quality of life. In other cases 
or if patient rejects surgery, a conservative approach to 
control symptoms and to prevent the osteonecrosis 
progression is administered.[42]
CONCLUSION
The pathophysiology of MRONJ is not completely 
elucidated, and an effective and appropriate therapy 
is still to be decided. It is crucial in future to improve 
the current knowledge about MRONJ and develop 
better strategies for its prevention and treatment. 
Governments and institutions should stimulate and 
support future research in this direction.
Financial support and sponsorship
Nil.
Conflicts of interest
There are no conflicts of interest.
REFERENCES
1. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, 
Mehrotra B, et al. American Association of  oral and maxillofacial 
surgeons position paper on medication‑related osteonecrosis of  
the jaw – 2014 update. J Oral Maxillofac Surg 2014;72:1938‑56.
2. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, 
Mehrotra B. American Association of  oral and maxillofacial 
surgeons position paper on bisphosphonate‑related 
osteonecrosis of  the jaws – 2009 update. J Oral Maxillofac Surg 
2009;67 5 Suppl: 2‑12.
3. Nussbaum SR, Younger J, Vandepol CJ, Gagel RF, Zubler MA, 
Chapman R, et al. Single‑dose intravenous therapy with 
pamidronate for the treatment of  hypercalcemia of  malignancy: 
Comparison of  30‑, 60‑, and 90‑mg dosages. Am J Med 
1993;95:297‑304.
4. Hortobagyi GN, Theriault RL, Lipton A, Porter L, 
Blayney D, Sinoff  C, et al. Long‑term prevention of  skeletal 
complications of  metastatic breast cancer with pamidronate. 
Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 
1998;16:2038‑44.
5. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, 
Lacombe L, et al. Long‑term efficacy of  zoledronic acid for the 
prevention of  skeletal complications in patients with metastatic 
hormone‑refractory prostate cancer. J Natl Cancer Inst 
2004;96:879‑82.
6. Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, 
Yee GC, et al. American society of  clinical oncology clinical 
practice guidelines: The role of  bisphosphonates in multiple 
myeloma. J Clin Oncol 2002;20:3719‑36.
7. Delmas PD. The use of  bisphosphonates in the treatment of  
Rosella, et al.: MRONJ: Diagnosis, treatment, and prevention
103   Journal of International Society of Preventive and Community Dentistry Mach-April 2016, Vol. 6, No. 2
osteoporosis. Curr Opin Rheumatol 2005;17:462‑6.
8. Medical economics. Physicians’ Desk Reference. 57th ed. 
Montvale, NJ: Medical Economics; 2003.
9. Delmas PD, Meunier PJ. The management of  Paget’s disease of  
bone. N Engl J Med 1997;336:558‑66.
10. Delmas PD. Clinical potential of  RANKL inhibition for the 
management of  postmenopausal osteoporosis and other 
metabolic bone diseases. J Clin Densitom 2008;11:325‑38.
11. Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, 
et al. Denosumab versus zoledronic acid for treatment of  bone 
metastases in men with castration‑resistant prostate cancer: A 
randomised, double‑blind study. Lancet 2011;377:813‑22.
12. Tenore G, Palaia G, Gaimari G, Brugnoletti O, Bove L, Lo 
Giudice R, et al. Medication‑Related Osteonecrosis of  the 
Jaws (MRONJ): Etiological update. Senses Sci 2014;1:147‑52.
13. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate‑associated 
osteonecrosis of  the jaw caused by soft tissue toxicity? Bone 
2007;41:318‑20.
14. Allen MR, Burr DB. The pathogenesis of  bisphosphonate‑related 
osteonecrosis of  the jaw: So many hypotheses, so few data. J Oral 
Maxillofac Surg 2009;67 5 Suppl: 61‑70.
15. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, 
Melakopoulos I, Bozas G, et al. Osteonecrosis of  the jaw in 
cancer after treatment with bisphosphonates: Incidence and risk 
factors. J Clin Oncol 2005;23:8580‑7.
16. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate‑related 
osteonecrosis of  the jaw: Background and guidelines for 
diagnosis, staging and management. Oral Surg Oral Med Oral 
Pathol Oral Radiol Endod 2006;102:433‑41.
17. Kos M, Junka A, Smutnicka D, Bartoszewicz M, Kurzynowski T, 
Gluza K. Pamidronate enhances bacterial adhesion to 
bone hydroxyapatite. Another puzzle in the pathology of  
bisphosphonate‑related osteonecrosis of  the jaw? J Oral 
Maxillofac Surg 2013;71:1010‑6.
18. Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of  osteonecrosis 
of  the jaw in cancer patients receiving denosumab: A 
meta‑analysis of  seven randomized controlled trials. Int J Clin 
Oncol 2014;19:403‑10.
19. Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, 
Manegold C, et al. Overall survival improvement in patients with 
lung cancer and bone metastases treated with denosumab versus 
zoledronic acid: Subgroup analysis from a randomized phase 3 
study. J Thorac Oncol 2012;7:1823‑9.
20. Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, 
Andreadis CG, et al. Longitudinal cohort study of  risk factors in 
cancer patients of  bisphosphonate‑related osteonecrosis of  the 
jaw. J Clin Oncol 2009;27:5356‑62.
21. Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, 
McClung M, et al. The incidence of  osteonecrosis of  the jaw in 
patients receiving 5 milligrams of  zoledronic acid: Data from 
the health outcomes and reduced incidence with zoledronic 
acid once yearly clinical trials program. J Am Dent Assoc 
2010;141:1365‑70.
22. Papapoulos S, Chapurlat R, Libanati C, Brandi ML, Brown JP, 
Czerwinski E, et al. Five years of  denosumab exposure in 
women with postmenopausal osteoporosis: Results from the 
first two years of  the FREEDOM extension. J Bone Miner Res 
2012;27:694‑701.
23. Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, 
et al. Prevalence of  osteonecrosis of  the jaw in patients 
with oral bisphosphonate exposure. J Oral Maxillofac Surg 
2010;68:243‑53.
24. Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, 
Pesce LL. Osteonecrosis of  the jaw and use of  bisphosphonates 
in adjuvant breast cancer treatment: A meta‑analysis. Breast 
Cancer Res Treat 2009;116:433‑9.
25. Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of  osteonecrosis 
of  the jaw in cancer patients receiving denosumab: 
A meta‑analysis of  seven randomized controlled trials. Int J Clin 
Oncol 2014;19(2):403‑10.
26. Coleman R, Woodward E, Brown J, Cameron D, Bell R, 
Dodwell D, et al. Safety of  zoledronic acid and incidence of  
osteonecrosis of  the jaw (ONJ) during adjuvant therapy in a 
randomised phase III trial (AZURE: BIG 01‑04) for women 
with stage II/III breast cancer. Breast Cancer Res Treat 
2011;127:429‑38.
27. Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, 
et al. Bevacizumab and osteonecrosis of  the jaw: Incidence 
and association with bisphosphonate therapy in three large 
prospective trials in advanced breast cancer. Breast Cancer Res 
Treat 2010;122:181‑8.
28. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, 
Stopeck AT, et al. Incidence, risk factors, and outcomes of  
osteonecrosis of  the jaw: Integrated analysis from three blinded 
active‑controlled phase III trials in cancer patients with bone 
metastases. Ann Oncol 2012;23:1341‑7.
29. Yamazaki T, Yamori M, Ishizaki T, Asai K, Goto K, 
Takahashi K, et al. Increased incidence of  osteonecrosis 
of  the jaw after tooth extraction in patients treated with 
bisphosphonates: A cohort study. Int J Oral Maxillofac Surg 
2012;41:1397‑403.
30. Bedogni A, Fusco V, Agrillo A, Campisi G. Learning from 
experience. Proposal of  a refined definition and staging system 
for bisphosphonate‑related osteonecrosis of  the jaw (BRONJ). 
Oral Dis 2012;18:621‑3.
31. Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A 
et al. Up to a quarter of  patients with osteonecrosis of  the jaw 
associated with antiresorptive agents remain undiagnosed. Br J 
Oral Maxillofac Surg 2015;53(1):13‑7.
32. Marx RE. Oral and Intravenous Bisphosphonate‑Induced 
Osteonecrosis of  the Jaw. Chicago, Ill, USA: Quintessence; 2007.
33. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, 
Roussou M, et al. Reduction of  osteonecrosis of  the jaw (ONJ) after 
implementation of  preventive measures in patients with multiple 
myeloma treated with zoledronic acid. Ann Oncol 2009;20:117‑20.
34. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, 
Saibene G, et al. Decreased occurrence of  osteonecrosis of  
the jaw after implementation of  dental preventive measures 
in solid tumour patients with bone metastases treated with 
bisphosphonates. The experience of  the National Cancer 
Institute of  Milan. Ann Oncol 2009;20:137‑45.
35. Vandone AM, Donadio M, Mozzati M, Ardine M, Polimeni MA, 
Beatrice S, et al. Impact of  dental care in the prevention 
of  bisphosphonate‑associated osteonecrosis of  the jaw: A 
single‑center clinical experience. Ann Oncol 2012;23:193‑200.
36. Damm DD, Jones DM. Bisphosphonate‑related osteonecrosis 
of  the jaws: A potential alternative to drug holidays. Gen Dent 
2013;61:33‑8.
37. Hellstein JW, Adler RA, Edwards B, Jacobsen PL, Kalmar JR, 
Koka S, et al. Managing the care of  patients receiving 
antiresorptive therapy for prevention and treatment of  
osteoporosis: Executive summary of  recommendations from the 
American Dental Association Council on Scientific Affairs. J Am 
Dent Assoc 2011;142:1243‑51.
Rosella, et al.: MRONJ: Diagnosis, treatment, and prevention
Journal of International Society of Preventive and Community Dentistry    104March-April 2016, Vol. 6, No. 2
38. Marx RE, Sawatari Y, Fortin M, Broumand V. 
Bisphosphonate‑induced exposed bone (osteonecrosis/
osteopetrosis) of  the jaws: Risk factors, recognition, prevention, 
and treatment. J Oral Maxillofac Surg 2005;63:1567‑75.
39. American Association of  Endodontists. Endodontic Implication 
of  Bisphosphonate‑Associated Osteonecrosis of  the Jaws. 
Chicago, IL: American Association of  Endodontists; 2010. p. 4.
40. Scoletta M, Arduino PG, Reggio L, Dalmasso P, Mozzati M. 
Effect of  low‑level laser irradiation on bisphosphonate‑induced 
osteonecrosis of  the jaws: Preliminary results of  a prospective 
study. Photomed Laser Surg 2010;28:179‑84.
41. Romeo U, Galanakis A, Marias C, Vecchio AD, Tenore G, 
Palaia G, et al. Observation of  pain control in patients with 
bisphosphonate‑induced osteonecrosis using low level 
laser therapy: Preliminary results. Photomed Laser Surg 
2011;29:447‑52.
42. Rugani P, Acham S, Kirnbauer B, Truschnegg A, 
Obermayer‑Pietsch B, Jakse N. Stage‑related treatment concept 
of  medication‑related osteonecrosis of  the jaw‑a case series. Clin 
Oral Investig 2015;19:1329‑38.
43. Carlson ER, Basile JD. The role of  surgical resection in the 
management of  bisphosphonate‑related osteonecrosis of  the 
jaws. J Oral Maxillofac Surg 2009;67 5 Suppl: 85‑95.
44. Brauner E, Guarino G, Jamshir S, Papi P, Valentini V, Pompa V, 
et al. Evaluation of  highly porous dental implants in postablative 
oral and maxillofacial cancer patients: A prospective pilot clinical 
case series report. Implant Dent 2015;24:631‑7.
45. Seth R, Futran ND, Alam DS, Knott PD. Outcomes of  
vascularized bone graft reconstruction of  the mandible in 
bisphosphonate‑related osteonecrosis of  the jaws. Laryngoscope 
2010;120:2165‑71.
46. Pompa G, Bignozzi I, Cristalli MP, Quaranta A, Di Carlo S. 
Bisphosphonates and Osteonecrosis of  the jaw: The oral 
surgeon’s perspective. Eur J Inflamm 2012;101:11‑23.
